Table 2.

In Vitro Effects of PF4, NAP-2, and IL-8 on the Survival of Different Types of CB Hematopoietic Progenitors Treated With 5-FU

Treatment of Cells (2.5 × 105)Total Hematopoietic Progenitors
After Treatment
CFU-GEMMBFU-ECFU-GMCFU-MK
1.PBS + PBS 25 ± 3 104 ± 10 145 ± 7 67 ± 4 
2.PBS + 5-FU 6 ± 1† 14 ± 3† 31 ± 5† 23 ± 3† 
3.PF4 1 μg/mL + 5-FU 12 ± 2* 42 ± 5* 97 ± 4* 55 ± 3* 
4.NAP-2 0.1 μg/mL + 5-FU 5 ± 1 25 ± 2* 59 ± 3* 36 ± 4* 
5.NAP-2 0.6 μg/mL + 5-FU 12 ± 2* 54 ± 4* 104 ± 11* 42 ± 5* 
6.IL-8 0.1 μg/mL + 5-FU 9 ± 2 48 ± 3* 92 ± 5* 41 ± 3* 
7.IL-8 0.6 μg/mL + 5-FU 12 ± 1* 36 ± 4* 81 ± 3* 39 ± 3* 
8.Protamine 10 μg/mL + 5-FU 9 ± 2 21 ± 3 42 ± 5 28 ± 4 
Treatment of Cells (2.5 × 105)Total Hematopoietic Progenitors
After Treatment
CFU-GEMMBFU-ECFU-GMCFU-MK
1.PBS + PBS 25 ± 3 104 ± 10 145 ± 7 67 ± 4 
2.PBS + 5-FU 6 ± 1† 14 ± 3† 31 ± 5† 23 ± 3† 
3.PF4 1 μg/mL + 5-FU 12 ± 2* 42 ± 5* 97 ± 4* 55 ± 3* 
4.NAP-2 0.1 μg/mL + 5-FU 5 ± 1 25 ± 2* 59 ± 3* 36 ± 4* 
5.NAP-2 0.6 μg/mL + 5-FU 12 ± 2* 54 ± 4* 104 ± 11* 42 ± 5* 
6.IL-8 0.1 μg/mL + 5-FU 9 ± 2 48 ± 3* 92 ± 5* 41 ± 3* 
7.IL-8 0.6 μg/mL + 5-FU 12 ± 1* 36 ± 4* 81 ± 3* 39 ± 3* 
8.Protamine 10 μg/mL + 5-FU 9 ± 2 21 ± 3 42 ± 5 28 ± 4 

CB NAMCS (106/mL and 2.5 × 105/well) were preincubated with or without different concentrations of PF4, NAP-2, or IL-8 for 48 hours. 5-FU at 2.5 μg/mL was then added for an additional 24-hour incubation. After incubation, cells were counted, washed 3 times, and then cultured in triplicate at 5 × 104 cells/0.25 mL/well in a 24-well plate in a methylcellulose system containing 10% FCS, recombinant human IL-3 (20 ng/mL), GM-CSF (20 ng/mL), and EPO (4 U/mL) for 14 days for CFU-GEMM, BFU-E, and CFU-GM, and in plasma clot for CFU-MK. Data are expressed as the mean ± SEM from 3 separate experiments.

*

P < .05 v PBS + 5-FU.

†

P < .05 v PBS + PBS.

View Large